Kan Chen

Title: The Innovations of Kan Chen

Introduction

Kan Chen is a notable inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative protein therapies. His work focuses on enhancing immune responses, which has important implications for cancer treatment.

Latest Patents

Kan Chen holds a patent for an IL-15 heterodimeric protein and its uses. This patent describes an IL-15 heterodimeric protein, such as an IL-15/IL-15Rα heterodimeric protein. The protein consists of two components: protein (I), which is recombinantly produced by combining IL-15 or a variant with a first Fc variant, and protein (II), which is either a second Fc variant or produced by combining IL-15Rα or a variant with a second Fc variant. The two Fc variants are linked via a 'Knob-into-Hole' mode. The IL-15 heterodimeric proteins exhibit significant anti-tumor activity, improved biological activity, and a prolonged in vivo half-life compared to the IL-15 molecule alone.

Career Highlights

Throughout his career, Kan Chen has worked with prominent companies in the pharmaceutical industry. He has been associated with Shanghai Hengrui Pharmaceutical Co., Ltd. and Jiangsu Hengrui Medicine Company Ltd. His expertise in protein engineering and immunology has positioned him as a key figure in the development of therapeutic solutions.

Collaborations

Kan Chen has collaborated with notable colleagues, including Xiangdong Qu and Xin Ye. These partnerships have facilitated advancements in his research and contributed to the success of his innovations.

Conclusion

Kan Chen's work in developing IL-15 heterodimeric proteins represents a significant advancement in immunotherapy. His contributions to biotechnology continue to influence the field and offer hope for improved cancer treatments.